This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cosmi, B. Articles by Weitz, J. I. Search for Related Content PubMed PubMed Citation Articles by Cosmi, B. Articles by Weitz, J. I.

(Circulation. 1997;95:118-124.)
© 1997 American Heart Association, Inc.

Articles

Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate

Benilde Cosmi, MD; James C. Fredenburgh, PhD; Janice Rischke, RT; Jack Hirsh, MD; Edward Young, PhD; Jeffrey I. Weitz, MD

McMaster University and Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada.

Correspondence to Dr Jeffrey Weitz, Hamilton Civic Hospitals Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3, Canada.

Background Nonspecific binding to plasma proteins decreases the anti–factor Xa (anti-Xa) activity of unfractionated heparin (UFH) but not that of low-molecular-weight heparin (LMWH). However, plasma proteins could influence the anti-thrombin (anti-IIa) activity of LMWH. To explore this possibility, we compared the effects of plasma proteins on the anti-IIa activities of UFH and LMWH. We also examined their effects on the anti-IIa activity of dermatan sulfate (DS) because, like UFH, DS binds to plasma proteins.

Methods and Results There was almost complete recovery of anti-IIa activity when UFH, LMWH, or DS was added to plasma from each of 20 healthy volunteers. The addition of a chemically modified heparin with low affinity for antithrombin III to plasma containing UFH increased the anti-IIa activity in a concentration-dependent fashion by displacing UFH from plasma proteins. In contrast, addition of low-affinity heparin had no effect on the anti-IIa activity of LMWH. LMWH does not bind to plasma proteins because the bulk of the LMWH chains are <6000 D, and only heparin fractions >6000 D bind nonspecifically to plasma proteins. As further evidence that plasma proteins do not influence the anti-IIa activity of LMWH, the rate of thrombin inhibition in plasma in the presence of LMWH is virtually identical to that in buffer containing physiological amounts of the major antithrombins. In contrast, with UFH or DS, the rate of thrombin inhibition is twofold slower in plasma than in buffer.

Conclusions Nonspecific binding of UFH to plasma proteins most likely contributes to the variable anti-IIa response to UFH in patients with thromboembolic disease. Although DS also binds to plasma proteins, the clinical significance of this finding is unclear. In contrast, because LMWH does not bind to plasma proteins, the anti-IIa activity of LMWH should be just as predictable as its anti-Xa activity.

Key Words: anticoagulants • heparin • plasma • proteins

This article has been cited by other articles:

				E. L. Breuhl, G. Moore, M. B. Brooks, and J. C. Scott-Moncrieff A Prospective Study of Unfractionated Heparin Therapy in Dogs With Primary Immune-Mediated Hemolytic Anemia J. Am. Anim. Hosp. Assoc., May 1, 2009; 45(3): 125 - 133. [Abstract] [Full Text] [PDF]

				P. C. Y. Liaw, R. C. Austin, J. C. Fredenburgh, A. R. Stafford, and J. I. Weitz Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II J. Biol. Chem., September 24, 1999; 274(39): 27597 - 27604. [Abstract] [Full Text] [PDF]

				D. L. Becker, J. C. Fredenburgh, A. R. Stafford, and J. I. Weitz Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II J. Biol. Chem., March 5, 1999; 274(10): 6226 - 6233. [Abstract] [Full Text] [PDF]

				J. I. Weitz, E. Young, M. Johnston, A. R. Stafford, J. C. Fredenburgh, and J. Hirsh Vasoflux, a New Anticoagulant With a Novel Mechanism of Action Circulation, February 9, 1999; 99(5): 682 - 689. [Abstract] [Full Text] [PDF]

				R. De Cristofaro, E. De Candia, and R. Landolfi Effect of High- and Low-Molecular-Weight Heparins on Thrombin-Thrombomodulin Interaction and Protein C Activation Circulation, September 29, 1998; 98(13): 1297 - 1301. [Abstract] [Full Text] [PDF]